Treatment of premature ejaculation with sertraline hydrochloride.
OBJECTIVE
To evaluate the efficacy of sertraline hydrochloride in the drug treatment of premature ejaculation (P.E.).


METHODS
Forty-six normally potent men, aged 22 to 63 years (mean 42 years) with premature ejaculation were treated with oral sertraline in a dose ranging study. All men were either married or in a stable relationship. The mean ejaculatory interval was 1 minute (range 0-5 min). All men were started on Sertraline 25 mg daily and were increased to 50 mg after 3 weeks and 100 mg after a further 3 weeks. None of the men received any formal psychosexual therapy.


RESULTS
With a dose of 25 mg, the mean ejaculatory interval increased to 7.6 min (range 0-20 min). With a dose of 50 mg, the mean ejaculatory interval increased to 13.1 min (range 7 min-anejaculation) with 4 men experiencing anejaculation. With a dose of 100 mg, the mean ejaculatory interval increased to 16.4 min (range 7 min-anejaculation), 10 men experiencing anejaculation. With a dose of 25 mg, 1 man described transient dizziness. With a dose of 50 mg, 1 man described some drowsiness and anorexia and 1 man experienced minor dyspepsia. With a dose of 100 mg, 2 men described erectile dysfunction and reduced libido, 2 men described transient drowsiness and anorexia, 2 men experienced minor dyspepsia and 2 men described feelings of anxiety.


CONCLUSIONS
Sertraline appears to be a useful agent in the pharmacological treatment of premature ejaculation.
McMahon
C G
CG
St. Luke's Hospital Complex, Sydney, Australia.
D000328:Adult; D004542:Ejaculation; D006801:Humans; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D017367:Selective Serotonin Reuptake Inhibitors / Q000627:therapeutic use*; D020280:Sertraline / Q000627:therapeutic use*; D012735:Sexual Dysfunction, Physiological / Q000188:drug therapy*
D017367:Selective Serotonin Reuptake Inhibitors; D020280:Sertraline